about
Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human PopulationsRandomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen.H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adultsA monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquineStrong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.The duration of in vitro stimulation with recall antigens determines the subset distribution of interferon-gamma-producing lymphoid cells: a kinetic analysis using the Interferon-gamma Secretion Assay.Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults
P50
Q30401304-62F8A21D-943C-4AE6-828B-1FB1675FE730Q33578064-6CA86095-E6A9-48E0-8A93-DB13864F5029Q34047556-E10DA69E-BF33-4AEF-A81B-BA49A0197032Q34598141-0DC78B85-C383-491B-AF8F-A7AD8BD047E9Q34989404-4C96CB38-1E3F-4302-B750-CD83CE79C50CQ35094040-73B2A221-37D9-4772-89FD-5C81339D1D69Q36978351-EEC3CC0E-4EB9-4C6E-9005-688DBADFB326Q37402867-2243854F-285A-47DB-A6A9-F9FF764A3863Q37643349-CAEF7F98-06A5-47DD-A204-1026AE0DAA5AQ39845365-FA431C57-7768-40EE-AF2C-A04F5A2AEB04Q42126049-96CA114A-54F5-48EB-AA06-AF12AD1D872EQ49110611-411DD437-1072-4C2D-B965-E4812A44293AQ49124572-8A3935B0-A874-42C6-97A0-721C34F3C29EQ49161794-C86AF8FD-2FE2-4349-A40E-87FB47E7DE17Q51751564-56D8B40A-8F2E-4794-89D7-8C4CA789D87EQ83681063-0E79529D-D443-4378-AAA8-866D04228505
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frédéric Clement
@ast
Frédéric Clement
@en
Frédéric Clement
@es
Frédéric Clement
@nl
Frédéric Clement
@sl
type
label
Frédéric Clement
@ast
Frédéric Clement
@en
Frédéric Clement
@es
Frédéric Clement
@nl
Frédéric Clement
@sl
altLabel
Frédéric Clement
@en
prefLabel
Frédéric Clement
@ast
Frédéric Clement
@en
Frédéric Clement
@es
Frédéric Clement
@nl
Frédéric Clement
@sl
P106
P108
P21
P31
P496
0000-0002-2720-3655